Lonza and Eclipse have entered an agreement for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Light Path Development Services. ET-101 is a novel therapeutic antibody designed to target cancer stem cells. Lonza will produce Phase I material at its development and manufacturing facility in Slough, UK.

Dr. Christopher Reyes, chief scientific officer of Eclipse Therapeutics, said, “Lonza’s best-in-class antibody manufacturing capabilities will greatly support our development strategy to deliver the highest quality and most effective therapeutics targeting cancer stem cells. Moving into cell line development and subsequent manufacturing represents an important milestone for Eclipse.”

“Lonza is excited that Eclipse has chosen us to support this innovative field of novel cancer therapeutics,” said Dr. Stephan Kutzer, chief operating officer of Lonza Custom Manufacturing. “We are pleased to offer development services specifically designed to support emerging companies during their early clinical milestones.”